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Background: During the aging process, skin shows visible changes, characterized by a loss of elasticity
and the appearance of wrinkles due to reduced collagen production and decreased elasticity of elastin
ﬁbers. Panax ginseng Meyer has been used as a traditional medicine for various diseases due to its wide
range of biological activities including skin protective effects. Ginsenosides are the main components
responsible for the biological activities of ginseng. However, the protective activities of an enzymatic
preparation of red ginseng against human skin aging have not been investigated.
Methods: The efﬁcacy of an enzyme-treated powder complex of red ginseng (BG11001) in preventing
human skin aging was evaluated by oral administration to 78 randomized individuals. All patients were
requested to take three daily capsules containing either 750 mg of BG11001 or a placebo vehicle for 24
wk; at the end of the testing period, skin roughness, elasticity, and skin water content were measured.
Results: BG11001 signiﬁcantly reduced the average roughness of eye wrinkles and the Global Photo
Damage Score compared with the placebo, although there were no signiﬁcant differences in arithmetic
roughness average between the groups. In addition, gross elasticity and net elasticity values increased,
and transepidermal water loss level decreased, indicating improved skin elasticity and moisture content.
Conclusion: In conclusion, enzyme-treated red ginseng extract signiﬁcantly improved eye wrinkle
roughness, skin elasticity, and moisture content. Moreover, enzyme-treated red ginseng extract would be
useful substance as a bio-health skin care product.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aging is a dynamic and highly complex process deﬁned by
multiple physiological changes over time. All bodily systems are
subject to the aging process and the integumentary system is not an
exception. The human skin covers the whole outer body, which
makes the skin the largest organ of the integumentary system. The
skin has multiple layers of ectodermal tissue and guards theedicinal Materials & Processing, C
ht  2015, The Korean Society of G
d/4.0/).underlying muscles, bones, ligaments, and internal organs. During
the process of aging, the skin changes show the most visible signs
characterized by decreased elasticity, increased roughness, uneven
skin tone with dark spots, and the formation of wrinkles [1].
Wrinkles on the face are the most dominantly recognized signs of
skin aging [2]. Over time, the epidermis becomes thinner, even
though the number of cell layers remains unchanged. Not only does
the dermal layer thin, but also less collagen is produced, and theollege of Life Science, Kyung Hee University, 1732, Deogyeong-daero, Giheung-gu,
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
Table 1
Compositions of the BG11001 and placebo tablets
Ingredient Tablet (mg) Percentage (%)
BG11001 tablet
BG11001 250 41.7
Microcrystalline cellulose 88.4 14.7
Dextrin 150 25
Maltitol syrup powder 96 16
Magnesium stearate 9 1.5
Silicon dioxide 3 0.5
HPMC 3.3 0.55
Glycerol fatty acid ester 0.3 0.05
Total 600 100
Placebo tablet
Microcrystalline cellulose 210 35
Lactose powder 331.5 55.25
Caramel coloring 1.32 0.22
Gardenia yellow pigment 0.78 0.13
Maltitol syrup powder 43.5 7.25
Magnesium stearate 9.3 1.55
HPMC 3.3 0.55
Glycerol fatty acid ester 0.3 0.05
Total 600 100
HPMC, hydroxypropylmethylcellulose.
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elasticity [3,4]. These changes in the structure of the skin cause the
skin to wrinkle and slacken. Facial skin sites like the corners of the
eyes are especially susceptible to wrinkle formation, which is also
popularly known as “crow’s feet”.
The maintenance of younger-looking skin is constantly desired
by a large proportion of the world’s population. Therefore, many
institutes and cosmetic and pharmaceutical companies have been
trying to develop functional cosmetic materials from natural sub-
stances such as herbs, roots, essential oils, and ﬂowers. Panax
ginseng has a history of medical use for over 5,000 yr. Panax derived
from Greek word “Panakos” presents Pandmeaning “all” and akos
meaning “cure”. Ginseng is said to mean “wonder of the world.”
Like the literal meaning of its name, Panax ginseng Meyer has been
used as a traditional medicine for various diseases with wide range
of biological activities, including anti-inﬂammatory [5], antioxidant
[6], antitumor [7], and antistress effects [8]. In recent studies, re-
searchers investigated the protective effects of Panax ginseng,
against the UVB-irradiation on epidermal keratinocytes and dermal
ﬁbroblasts. They found that ginseng recovered the UVB-induced
decrease in antiapoptotic gene expression in the human keratino-
cytes and dermal ﬁbroblast, indicating that ginseng can protect
cells from apoptosis caused by strong UVB radiation [9]. Another
study showed that ginseng extract induced type I collagen pro-
duction in human dermal ﬁbroblast cells by activation of Smad
signaling, suggesting ginseng as a potential candidate as a wrinkle-
reducing agent by topical application [10].
Ginsenosides are the pharmacologically active components and
are responsible for the biological functions in ginseng. Amongmore
than 50 isolated ginsenosides, major ones (Rb1, Rb2 , Rc, Rd, Re, Rg1,
and Rf) constitute more than 80% of the total ginsenosides and the
minor ginsenosides (F1, F2, Rg3, Rh1, Rh2 compound Y, compound
Mc, and compound K) are present at low concentrations in ginseng
[11]. Many studies show that the minor ginsenosides have phar-
macologically active than major ones because absorption of major
ginsenosides by the gastrointestinal tract is quite poor [12]. As a
result, the minor ginsenosides have been demonstrated to be
pharmaceutically active and excellent potential drug candidates
[13]. However, hydrolysis of sugar moieties to convert major gin-
senosides to minor forms by digestive enzymes in gastrointestinal
tract are quite low even though the minor ginsenosides are more
easily absorbed into the bloodstream [12]. Since it is possible to
transform into minor ginsenosides by enzyme treatment, enzyme-
treated red ginseng has been shown to have strong antiwrinkle
activity and reduced toxicity in in vitro and animal studies [14].
Also, our previous studies demonstrated that enzyme-treated
ginseng protected UVB-induced skin damage through the regula-
tion of procollagen type I and matrix metalloproteinase (MMP)-1
expression in hairless mice [15,16]. However, the protective activity
of the enzymatic preparation of red ginseng against human skin
aging has not been investigated. In this study, we investigated
whether enzyme-treated powder complex of red ginseng
(BG11001) prevents human skin aging by reducing skin wrinkles
and enhancing elasticity.
2. Materials and methods
2.1. Preparation of enzyme-treated powder complex of red ginseng
(BG11001)
Enzyme-treated extract of red ginseng was prepared following a
patented protocol [Korea patent no. 10-2011-0091287 (in private),
in press] [15]. Red ginseng powderwith 10 times volume of distilled
water was mixed for 2 h using a homo-mixer and then enzyme
treated for 24 h at 55C. Enzyme-treated red ginseng was heated upto 90C, cooled down to 10e15C, and then centrifuged. Superna-
tant was concentrated, added 10 times volume of 50% ethanol, and
extracted for 40 min at 85C. Finally, the same amount of malt
dextrin was added, spray dried and used as raw material of
BG11001.
For thin layer chromatography analysis of the ginsenoside
compositions, the total ginsenosides were spotted together with
the standard 20(S)-protopanaxdiol (PPD) or 20(S)-protopanaxtriol
samples on thin layer chromatography plate (silica gel 60 F254,
Merck) containing CHCl3-MeOH-H2O (65:35:10, v/v), thereafter
stained by spraying with 30% H2SO4, followed by heating at 105C.
2.2. Study design
This study was designed as a randomized, double-blind study to
assess the effects of 250 mg of oral BG11001 given thrice a day for
24 wk of the trial period in patients with cutaneous photoaging.
The compositions of the BG11001 and placebo tablets are shown in
Table 1.
2.3. Global photodamage score
Patients’ periorbital wrinkles were evaluated based on a global
photodamage score (0, none; 1, none/mild; 2, mild; 3, mild/mod-
erate; 4, moderate; 5, moderate/severe; 6, severe; 7, very severe) at
Wk 0 (baseline). If the investigators’ evaluations differed, low-grade
efﬁcacy and high-grade adverse effect were selected. The patients’
periorbital wrinkles were classiﬁed into eight grades.
2.4. Participants
Ninety-eight healthy Asian women, aged between 40 and 60 yr,
clinically diagnosed with a global photodamage score of 2e6 ac-
cording to the Jung score of photoaging of facial skinwere recruited
and included in this study after written informed consent. Those
who experienced any esthetic procedure like peeling, laser, intense
pulsed light, dermabrasive therapies, or have used any antiaging
cream or nutritional supplement within the past 3 mo could not
participate in the study. Participants were requested not to expose
themselves to sunlight during the trial. They were also requested
not to use lotions, creams, or other products on the face and fore-
arms. Participants agreed to follow these instructions during the
J Ginseng Res 2016;40:260e268262trial period. On completion of the abovementioned enrollment
process of the participants in the study, the study coordinator
allocated them into each group.2.5. Groups
Participants were randomly allocated into two groups which
were of the same size and matched on the basis of global photo-
damage score and age. A computer-generated table of random
numbers was prepared in advance and was later used to randomly
allocate participants into one of the two groups. Participants in the
BG11001 experimental group were supplemented with “enzyme-
treated powder complex of red ginseng (BG11001)” capsules and
those in the placebo control group with placebo capsules. Those
who used any nutritional supplement other than the test material
during the trial period were dropped from the trial.
The trial started in the summer of 2012 and was completed in
the winter of 2013. The protocol has been reviewed and approved
by the Ethics Committee (Oriental Hospital of Se-Myung University,
Jecheon, South Korea) and was approved in June 2012. The study
was carried out in accordance to the Declaration of Helsinki (1964)
changed in Tokyo (2004) and Seoul (2008).2.6. Treatment
All patients were requested to take three capsules daily for 24
wk. The capsules were prepared to contain either 250 mg of
BG11001 or the excipients of lactose powder, microcrystalline cel-
lulose, and powered maltitol syrup. Participants were instructed to
take one capsule in the morning, another in the afternoon, and the
other in the evening with a glass of water. Placebo and BG11001
capsules were identical in color, taste, odor, and packaging and
their content was blinded to the participants and investigator.2.7. Blinding
Only the study coordinator knew the group allocation and
prepared the capsules for both groups accordingly. Both the par-
ticipants and the investigator were blinded to the information on
the group allocation until the end of the study. Allocation
concealment was maintained using an opaque envelope. Group
allocation information was opened to the participant at the end of
the trial period.2.8. Compliance
Those participants whose compliance was under 80% were
dropped from the study.Fig. 1. Thin liquid chromatography proﬁles of crude red ginseng ginsenosides before
and after treatment of enzyme. CK, compound K; PPD, 20(S)-protopanaxdiol (PPD);
PPT, 20(S)-protopanaxtriol.2.9. Serology
All parameters were measured at baseline and after 24 wk of
supplementation. Blood samples were collected from fasting par-
ticipants at baseline and after a 24-wk supplementation. To eval-
uate the safety of oral administration of BG11001, creatinine,
albumin, total protein, total cholesterol, high-density lipoprotein-
cholesterol, low-density lipoprotein-cholesterol, and glutamic-
oxalacetic transaminase, glutamic-pyruvic transaminase, gamma-
glutamyltransferase of serum were determined. Other parameters
analyzed were white blood cells, red blood cells, mean corpuscular
volume, hemoglobin, hematocrit, and platelet count. Speciﬁc
gravity, pH, protein, glucose, blood (red blood cells), human cho-
rionic gonadotropin of urine were also investigated.2.10. Noninvasive measurements of the skin
All measurements were performed under standardized condi-
tions, i.e., room temperature of 22  2oC and a relative humidity
level of 45  5%. An acclimatization time of at least 30 min was
respected before measurements started.
Microrelief (roughness) of the skin was measured with a skin
visiometer SV 600 (Courage-Khazaka, Cologne, Germany). Investi-
gated roughness parameters were R3 (average roughness) and R5
(arithmetic average roughness). Elastic properties of the skin were
measured with a Cutometer (Courage-Khazaka, Cologne, Ger-
many). Investigated elastic parameters were R2 (gross elasticity)
and R5 (net elasticity). Hydration, transepidermal water loss
(TEWL), elastic properties, and microrelief of the skin were evalu-
ated on the crow’s feet area at baseline and after 24 wk of sup-
plementation with the following noninvasive methods. Hydration
level and TEWL of the skin surface was measured with the Corne-
ometer CM 825 (Courage-Khazaka, Cologne, Germany) and Tewa-
meter TM300 (Courage-Khazaka, Cologne, Germany). Elastic
properties of the skin were measured with the Cutometer
(Courage-Khazaka, Cologne, Germany).
2.11. Statistical analysis
Results were determined using PRISM Statistical Analysis Sys-
tem (Version 5, GraphPad, La Jolla, CA, USA). Differences between
groups were evaluated with Student t test and differences within
groups were analyzed with analysis of covariance. A value of
p < 0.05 was considered signiﬁcant.
3. Results
3.1. Ginsenoside composition changes of red ginseng powder by
enzyme treatment
When red ginseng powder was enzyme treated, ginsenoside
compositions were changed which showed signiﬁcantly increased
F2, RdþRe, F1þRh1, and C-K (Fig. 1 and Table 2). Even if enzyme-
treated red ginseng contained relatively high amounts of
ginsenosides-Rd and Re, ginsenosides Re as a 20(S)-protopanaxtriol
type saponin [17] was almost unhydrolyzed by the enzyme.
Ginsenoside-Rd is an intermediate product hydrolyzed from PPD
type saponin (e.g., ginsenosides-Rb1, -Rb2, and Rc), thus, it has a
Table 2
Changes in ginsenoside composition
Ginsenoside Content (%) Changes (%)
Before After
C-K d 6.41 [ 6.41
F1þRh1 d 7.26 [ 7.26
F2 d 40.78 [ [ 40.78
Rg1 20.22 d Y Y 20.22
Rf 12.60 d Y Y 12.60
RdþRe 14.51 27.17 [ [ 12.66
Rc 25.27 18.38 Y 6.89
Rb1 25.27 d Y Y 25.27
C-K, compound K.
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F1þRh1were also increased in enzyme-treated red ginseng, but the
portion of the total amount from those ginsenosides was very
small. In the case of ginsenosides-F2, it is also hydrolyzed from a
PPD-based major saponin, but the F2 content of the enzyme-
treated red ginseng was relatively high and with content varia-
tion (coefﬁcient of variation) of each batch was quite low (11% in lab
scale and 5.7% in scale-up). In addition, our previous studies
demonstrated that enzyme-treated ginseng (index material: gin-
senosides F2) protected UVB-induced skin damage through the
regulation of procollagen type I and MMP-1 expression in hairless
mice [15,16]. Therefore, ginsenoside-F2 is considered as an index
material of enzyme-treated red ginseng (BG11001).
3.2. Demographics of participants
In total, 98 women were enrolled and randomized into two
groupsdplacebo and BG11001. Twenty out of the initial 98 enrolled
women were excluded from subsequent analysis for the followingAssessed for eligibility
(n = 98)
Received placebo 
(n = 39)
Withdrawn 
(n = 0)
Completed trial 
(n = 39)
Fig. 2. Study ﬂowchart of the particreasons: (1) agreement withdrawal/treatment refusal (n ¼ 6); (2)
noncompliance (n¼ 5); (3) intake of prohibited medication (n¼ 4);
(4) exclusion criteria violation (n ¼ 2); (5) side effects (n ¼ 2; right
anterior cruciate ligament rupture and ﬁnger fracture); and (6)
agreement acquisition violation (n ¼ 1). Thus, the number for ﬁnal
data analysis was 78 (BG11001: n ¼ 39, placebo: n ¼ 39) (Fig. 2). In
the treatment group (n ¼ 39), the average age was 51.16  4.41 yr,
and the average weight was 56.71  7.07 kg; in the placebo group
(n ¼ 39), the average age was 51.14  3.83 yr, and average weight
was 59.26  7.91 kg. The demographic data of the participants are
summarized in Table 3. The Student t test revealed no signiﬁcant
difference in initial age or weight. Laboratory evaluations revealed
no signiﬁcant abnormalities in complete blood count and chemis-
try (Table 4).
3.3. Analysis of BG110001 effect on eye wrinkles in human skin
Comparisons of eye wrinkles before and after 8 wk, 16 wk, and
24 wk of BG11001 consumption between the treatment group and
the placebo group, as measured with the SV600 visiometer and
Global Photo Damage Score (GPDS) are shown in Table 5e7. At 8wk,
value of average roughness (R3) for eye wrinkles was reduced
0.007  0.009 AU in the treatment group and 0.003  0.011 AU in
the placebo group. Those reductions were similarly maintained
after 16 wk (0.005 AU in the treatment group and 0.003 AU in the
placebo group) and 24 wk (0.006 AU in the treatment group and
0.004 AU in the placebo group), respectively (Table 5). Those R3
values were signiﬁcantly decreased within the treatment group,
but not in the placebo group. Therefore, each improvement of R3
values in the treatment group at each time point showed statistical
signiﬁcance after adjustment with baseline. However, the value of
arithmetic roughness average (R5) did not show improvement by
BG11001. When the R5 values were compared within the group, 
Excluded (n = 20) 
Agreement withdrawal/treatment refusal 
(n = 6) 
Noncompliance (n = 5) 
Intake of prohibited medication (n = 4) 
Exclusion criteria violation (n = 2) 
Side effects (n = 2) 
Received BG11001 
(n = 39)
Withdrawn 
(n = 0)
Completed trial 
(n = 39)
ipants describing trial progress.
Table 3
Demographics of the participants in each group
BG11001 Placebo p
No. enrolled 49 49
No. completed 39 39
Average age (yr) 51.16  7.07 51.15  3.83 0.981
Average weight (kg) 56.71  7.07 59.26  7.91 0.095
Data are presented as mean  SD.
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with baseline, we could not ﬁnd any statistical difference (Table 6).
Global photodamage was scored using a randomized and
double-blindedmethod. Even if GPDSmight be judged subjectively,
only BG11001 signiﬁcantly decreased the scores. Decreased scores
were observed from 8 wk of treatment and tended to decline until
24 wk (Table 7).
3.4. Observation of improved skin elasticity
The values of gross elasticity (R2) and net elasticity (R5) were
measured with a Cutometer (Tables 8 and 9). After BG11001
treatment, R2 values were increased in each time point, from
0.89 0.05 AU at baseline to 0.910.04 AU at 24 wk, but not in the
placebo group. Within the treatment group, R2 values were sta-
tistically different after 16 wk and 24 wk. Also, when we compared
R2 values between groups using analysis of covariance, after
adjustment with baseline, the gross skin elasticity was statistically
improved by enzyme-treated red ginseng extract (Table 8). Then,
net elasticity (R5) was measured and showed that R5 values were
signiﬁcantly increased within the treatment group. In addition,
statistics of comparison between the treatment and placebo group
showed that BG11001 improved net skin elasticity (Table 9).
3.5. Changes of the moisture content of the stratum corneum and
TEWL
The hydration level of the stratum corneumwasmeasured using
a corneometer (Table 10). During the treatment of BG11001 for 24
wk, hydration level was decreased from 8 wk treatment. However,Table 4
Serology data
BG11001
Before After 24 wk
Average  SD
Hematology
WBC 5.92  1.37 5.90  1.33 0
RBC 4.31  0.28 4.39  0.25 0
Hemoglobin 13.26  0.85 13.57  0.84 0
Hematocrit 39.99  2.31 40.82  2.23 0
Platelets 239.08  46.76 247.98  48.90 0
Blood chemistry
ALP 225.18  68.63 251.12  72.89 0
AST 23.04  5.31 26.31  13.42 0
ALT 20.00  8.14 24.80  16.11 0
g-GTP 22.49  18.34 25.12  22.09 0
Total protein 7.16  0.31 7.16  0.34 0
Albumin 4.45  0.17 4.49  0.22 0
Creatinine 0.85  0.12 0.80  0.11 0
MCV 92.84  3.31 92.91  3.17 0
Glucose 85.94  9.05 91.55  18.37 0
Total cholesterol 206.14  37.72 203.43  35.72 0
HDL 61.57  15.55 61.29  15.89 0
LDL 127.20  34.03 129.31  34.68 0
Triglycerid 150.39  93.85 134.53  77.14 0
*p < 0.05, **p < 0.01 by Student’s t-test for comparison between before and 24 wk treate
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GTP
protein; MCV, mean corpuscular volume; RBC, red blood cells; Std., standard deviation;decreased hydration level was maintained until 24 wk in the
treatment group. In addition, the degrees of decrease were much
smaller than those in the placebo group. Then, the measurement of
TEWL was performed with a Tewameter (Table 11). After 24 wk of
BG11001 consumption, TEWL values were decreased in the treat-
ment group, even at 8wk of treatment; however, TEWL values were
increased in the placebo group in each time point for 24 wk. Also,
the statistics of comparison between groups at the 24 wk time
point, showed that BG11001 signiﬁcantly prevented TEWL.4. Discussion
The present study demonstrated that 24-wk oral administra-
tion of enzyme-treated powder complex of red ginseng (BG11001)
has substantial beneﬁts over the placebo in the improvement of
eye wrinkle roughness, elasticity, and skin moisture content. The
administration of BG11001 signiﬁcantly reduced average rough-
ness (R3) of eye wrinkles and GPDS score, compared with a pla-
cebo; although, there was no signiﬁcant difference in arithmetic
roughness average (R5) between both groups. In addition, gross
elasticity (R2) and net elasticity (R5) values were increased and
TEWL level was decreased, indicating improved skin elasticity and
moisture content. However, hydration levels of the stratum cor-
neum were decreased even in the treatment group. To interpret
this result, we needed to consider the weather conditions during
the study. When the study was started at early July, the weather
was humid (average humidity: 78.5%) and warm (average tem-
perature: 23.4C) (Korea Meteorological Administration). Howev-
er, as the treatment proceeded, the weather became drier
(average humidity: 69.4% at the 24 wk time point) and colder
(average temperature: 5.2C at the 24 wk time point), meaning
that skin could have lost moisture and elasticity more than the
baseline time point [18]. Therefore, with considering the weather
conditions, results should be reinterpreted, as eye wrinkle
roughness was remarkably improved by showing the average
roughness (R3) value and GPDS score. Even though values of
arithmetic roughness average (R5) were not decreased enough to
show any statistical difference, BG11001 prevented worsening ofp Placebo p
Before After 24 wk
Average  SD
.940 5.79  1.39 5.87  1.45 0.564
.002** 4.31  0.27 4.33  0.26 0.271
.002** 13.22  0.90 13.36  0.89 0.048*
.001** 40.02  2.31 40.26  2.12 0.204
.041* 247.51  60.29 246.41  65.58 0.793
.000** 215.14  53.37 240.96  65.18 0.000**
.066 23.76  8.31 24.45  8.43 0.430
.011* 22.24  14.52 23.33  14.61 0.375
.086 21.06  22.45 18.90  19.84 0.033*
.885 7.24  0.31 7.15  0.32 0.042*
.077 4.49  0.20 4.46  0.18 0.261
.004** 0.82  0.08 0.81  0.13 0.425
.682 92.95  3.50 92.98  3.54 0.858
.029* 87.69  11.48 91.53  19.29 0.048*
.471 195.06  24.11 192.49  24.63 0.031*
.806 61.98  13.90 61.39  14.84 0.686
.490 116.14  26.03 113.86  29.75 0.402
.219 124.49  73.69 115.27  58.02 0.349
d group.
, guanosine-50-triphosphate; HDL, high density lipoprotein; LDL, low density lipo-
WBC, white blood cells.
Table 5
Average roughness (R3) value changes
BG11001 Placebo p1) p2)
Arbitrary units (Average  SD)
SV600 (R3) Baseline 0.037  0.012 0.040  0.013 0.280
After 8 wk 0.030  0.008 0.037  0.012 0.004 0.004**
Difference3) 0.007  0.009 0.003  0.011 0.095
P4) 0.000** 0.057
After 16 wk 0.032  0.008 0.037  0.011 0.008 0.014*
Difference5) 0.005  0.011 0.003  0.010 0.226
P4) 0.003** 0.106
After 24 wk 0.031  0.007 0.036  0.010 0.010 0.017*
Difference6) 0.006  0.011 0.004  0.009 0.382
P4) 0.004** 0.018*
* p < 0.05 by Student t-test for comparison with placebo group.
** p < 0.01 by Student t-test for comparison with placebo group.
1) Compared between groups: p-value by Student t-test.
2) Compared between groups: p-value by analysis of covariance (adjustment with baseline).
3) After 8 wk e baseline.
4) Compared within groups: p-value by paired t-test.
5) After 16 wk e baseline.
6) After 24 wk e baseline.
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conditions. With the same point of view, skin elasticity (R2 and
R5) and moisture content (TEWL) after treatment was substan-
tially improved, and decreased skin hydration was prevented by
BG11001, even with poor weather conditions for skin.
The primary cause for eye wrinkles, such as crow’s feet, is
exposure to sunlight. Sunlight ages the skin, and it also encour-
ages people to squint, wrinkling the skin around their faces. In
UV-damaged skin, increased MMP-1 triggers collagen degrada-
tion, especially collagen type I which is a source of structural
support in the dermis [19]. Also, UV irradiation increased the
expression of activator protein-1, which in turn interferes with
the synthesis of collagen type I by blocking transforming growth
factor-b1 and procollagen type I [20,21]. In a previous study,
Panax ginseng restored decreased expression of transforming
growth factor-b1 and TIMP-1 (Tissue Inhibitor of Metal-
loproteinase-1) and increased expression of MMP-1. Panax
ginseng also markedly attenuated MMP-1 expression. Those
regulations ﬁnally increased collagen type I (or procollagen typeTable 6
Arithmetic roughness average (R5) value changes
BG11001
Arbitrary uni
SV600 (R5) Baseline 0.017  0.008
After 8 wk 0.014  0.006
Difference3) 0.004  0.006
p4) 0.000**
After 16 wk 0.015  0.006
Difference5) 0.003  0.008
p4) 0.026*
After 24 wk 0.015  0.006
Difference6) 0.003  0.007
p4) 0.020*
* p < 0.05 by Student t-test for comparison with placebo group.
** p < 0.01 by Student t-test for comparison with placebo group.
1) Compared between groups: p-value by Student t-test.
2) Compared between groups: p-value by analysis of covariance (adjustment with base
3) After 8 wk e baseline.
4) Compared within groups: p-value by paired t-test.
5) After 16 wk e baseline.
6) After 24 wk e baseline.I) expression [15,16,22]. Also, other studies observed that Panax
ginseng induces collagen type I synthesis through activation of
Smad or peroxisome proliferator-activated receptor-delta
signaling [10,23]. In addition, enzyme-treated extract of red
ginseng reversed the inhibitory effects of UV irradiation on
ﬁlaggrin and proﬁlaggrin production in both the epidermis and
dermis in mice [15]. These results are important because ﬁlag-
grin in stratum corneum are incorporated into lipid envelopes
and release free amino acids to assist in water retention [24e26].
Another previous study reported that dietary supplementation of
red ginseng protected skin from UV-induced dryness with an
accumulation of ceramides via elevated expression of serine
palmitoyltransferase, a key enzyme involved in de novo ceramide
synthesis [27]. With all these previous results, we could suggest
that BG11001 improved human eye wrinkle roughness by the
regulation of collagen type I expression, and BG11001 was also
able to increase skin elasticity and maintain moisture content by
inhibition of ﬁlaggrin expression and elevation of serine palmi-
toyltransferase expression.Placebo p1) p2)
ts (Average  SD)
0.022  0.009 0.039
0.016  0.007 0.074 0.927
0.005  0.008 0.407
0.000**
0.017  0.008 0.079 0.722
0.004  0.010 0.530
0.016*
0.016  0.007 0.305 0.259
0.005  0.008 0.139
0.000**
line).
Table 7
Global photodamage score value changes
BG11001 Placebo p1) p2)
Arbitrary units (Average  SD)
GPDS Baseline 3.31  1.15 3.44  1.25 0.639
After 8 wk 3.15  1.04 3.41  1.21 0.318 0.262
Difference3) 0.15  0.75 0.03  0.54 0.386
p4) 0.205 0.767
After 16 wk 3.13  1.01 3.33  1.13 0.400 0.397
Difference5) 0.18  0.64 0.10  0.60 0.586
p4) 0.026* 0.016*
After 24 wk 3.05  1.03 3.38  1.14 0.178 0.062
Difference6) 0.26  0.60 0.05  0.61 0.135
p4) 0.010* 0.599
* p < 0.05 by Student t-test for comparison with placebo group.
** p < 0.01 by Student t-test for comparison with placebo group.
1) Compared between groups: p by Student t-test.
2) Compared between groups: p by analysis of covariance (adjustment with baseline).
3) After 8 wk e baseline.
4) Compared within groups: p by paired t-test.
5) After 16 wk e baseline.
6) After 24 wk e baseline.
Table 8
Skin elasticity (R2) value changes
BG11001 Placebo p1) p2)
Arbitrary units (Average  SD)
Cutometer (R2) Baseline 0.89  0.05 0.86  0.07 0.185
After 8 wk 0.90  0.04 0.86  0.05 0.000 0.000**
Difference3) 0.01  0.05 0.01  0.08 0.118
p4) 0.058 0.485
After 16 wk 0.91  0.05 0.87  0.07 0.002 0.003**
Difference5) 0.02  0.04 0.00  0.50 0.040*
p4) 0.006** 0.732
After 24 wk 0.91  0.04 0.87  0.07 0.003 0.006**
Difference6) 0.02  0.05 0.00  0.07 0.108
p4) 0.011* 0.946
* p < 0.05 by Student t-test for comparison with placebo group.
** p < 0.01 by Student t-test for comparison with placebo group.
1) Compared between groups: p by Student t-test.
2) Compared between groups: p by analysis of covariance (adjustment with baseline).
3) After 8 wk e baseline.
4) Compared within groups: p by paired t-test.
5) After 16 wk e baseline.
6) After 24 wk e baseline.
Table 9
Skin elasticity (R5) value changes
BG11001 Placebo p1) p2)
Arbitrary units (Average  SD)
Cutometer (R5) Baseline 0.68  0.18 0.62  0.14 0.127
After 8 wk 0.75  0.19 0.66  0.15 0.021 0.071
Difference3) 0.07  0.12 0.04  0.08 0.160
p4) 0.001** 0.006**
After 16 wk 0.79  0.21 0.67  0.17 0.009 0.033*
Difference5) 0.11  0.19 0.05  0.16 0.138
p4) 0.001** 0.045*
After 24 wk 0.78  0.22 0.65  0.16 0.004 0.014*
Difference6) 0.10  0.16 0.03  0.16 0.043
p4) 0.000** 0.246
* p < 0.05 by Student t-test for comparison with placebo group.
** p < 0.01 by Student t-test for comparison with placebo group.
1) Compared between groups: p by Student t-test.
2) Compared between groups: p by analysis of covariance (adjustment with baseline).
3) After 8 wk e baseline.
4) Compared within groups: p by paired t-test.
5) After 16 wk e baseline.
6) After 24 wk e baseline.
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Table 10
Skin hydration value changes
BG11001 Placebo p1) p2)
Arbitrary units (Average  SD)
Corneo-meter Baseline 72.23  10.20 70.90  11.77 0.692
After 8 wk 67.79  9.57 65.46  9.67 0.222 0.083
Difference3) 4.44  8.46 5.44  8.54 0.149
p4) 0.058 0.485
After 16 wk 65.67  10.34 63.43  9.29 0.074 0.008**
Difference5) 6.56  8.65 7.46  11.68 0.036
p4) 0.282 0.071
After 24 wk 67.49  10.49 63.89  10.87 0.090 0.005**
Difference6) 4.74  9.19 7.01  12.96 0.005
p4) 0.172 0.013*
* p < 0.05 by Student t-test for comparison with placebo group.
** p < 0.01 by Student t-test for comparison with placebo group.
1) Compared between groups: p by Student t-test.
2) Compared between groups: p-value by analysis of covariance (adjustment with
baseline).
3) After 8 wk e baseline.
4) Compared within groups: p-value by paired t-test.
5) After 16 wk e baseline.
6) After 24 wk e baseline.
Table 11
Transepidermal water loss value changes
BG11001 Placebo p1) p2)
Arbitrary units (Average  SD)
Tewa-meter Baseline 14.29  2.60 14.94  3.25 0.332
After 8 wk 13.67  2.47 15.16  3.98 0.051 0.062
Difference3) 0.62  1.79 0.22  2.47 0.091
p4) 0.039 0.580
After 16 wk 13.68  2.62 14.96  3.73 0.083 0.109
Difference5) 0.61  0.96 0.02  2.56 0.154
p4) 0.000** 0.958
After 24 wk 13.75  2.92 15.30  3.12 0.027 0.030*
Difference6) 0.53  1.81 0.36  2.57 0.081
p4) 0.073 0.391
* p < 0.05 by Student t-test for comparison with placebo group.
** p < 0.01 by Student t-test for comparison with placebo group.
1) Compared between groups: p by Student t-test.
2) Compared between groups: p-value by analysis of covariance (adjustment with
baseline).
3) After 8 wk e baseline.
4) Compared within groups: p-value by paired t-test.
5) After 16 wk e baseline.
6) After 24 wk e baseline.
S.-Y. Park et al / Effect of enzyme-reated red ginseng on skin 267In this study, we used oral administration of BG11001 despite
the possibility of oral intake delaying the effect on skin because the
substance should be absorbed andmetabolized. However, there are
more beneﬁts than topical application. Firstly, the aged do not
absorb topical substances more rapidly than the young, probably
less [28]. Secondly, when Panax ginseng is administrated orally, skin
care effects would be better with its wide range of biological ac-
tivities. For example, it promotes skin cell regeneration by a wound
healing effect [29] and also has the effect of boosting blood circu-
lation as well as detoxifying the blood [30,31]. Thirdly, with oral
intake we did not need to be worried about topical skin irritation.
Furthermore, there was no clinically signiﬁcant adverse effects of
BG11001 during the study.
In conclusion, enzyme-treated red ginseng extract signiﬁcantly
improved eye wrinkle roughness, skin elasticity, and moisture
content. Moreover, enzyme-treated red ginseng extract would be
useful substance as a bio-health skin care product.
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